Previous close | 3.9000 |
Open | 4.2000 |
Bid | 0.0000 |
Ask | 5.0000 |
Strike | 70.00 |
Expiry date | 2024-10-18 |
Day's range | 3.9000 - 4.3000 |
Contract range | N/A |
Volume | |
Open interest | 20 |
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced updated data from the ongoing Phase 1 dose escalation portion of the VELA clinical trial of BLU-222, an investigational, highly selective and potent CDK2 inhibitor, in combination with ribociclib and fulvestrant in patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. The data, which mark the first promising clinical results for a CDK2 inhibitor in combination with an app
If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost...
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.